Tayyiaba Iqbal

Dr. Tayyiaba Iqbal


Research Focus & Metrics

Representative Publications

View All Publications
2 June 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
SKShoaib Khan
Shoaib Khan
RHRafaqat Hussain
Rafaqat Hussain
YKYousaf Khan
Yousaf Khan
TITayyiaba Iqbal
Tayyiaba Iqbal
MKMuhammad Bilal Khan
Muhammad Bilal Khan
SMSaedah R. Al Mhyawi
Saedah R. Al Mhyawi

5 July 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
SKShoaib Khan
Shoaib Khan
RHRafaqat Hussain
Rafaqat Hussain
YKYousaf Khan
Yousaf Khan
TITayyiaba Iqbal
Tayyiaba Iqbal
SCSampath Chinnam
Sampath Chinnam
ADAyed A. Dera
Ayed A. Dera

19 March 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
TITayyiaba Iqbal
Tayyiaba Iqbal
SKShoaib Khan
Shoaib Khan
FRFazal Rahim
Fazal Rahim
RHRafaqat Hussain
Rafaqat Hussain
YKYousaf Khan
Yousaf Khan
MKM.M. Khowdiary
M.M. Khowdiary

16 April 2024 in Results in Chemistry
Verified
Journal Article
Open access
RHRafaqat Hussain
Rafaqat Hussain
HUHayat Ullah
Hayat Ullah
SKShoaib Khan
Shoaib Khan
YKYousaf Khan
Yousaf Khan
TITayyiaba Iqbal
Tayyiaba Iqbal
MAMohammad Javed Ansari
Mohammad Javed Ansari

10 September 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
TITayyiaba Iqbal
Tayyiaba Iqbal
SKShoaib Khan
Shoaib Khan
FRFazal Rahim
Fazal Rahim
MTMuhammad Tayyab
Muhammad Tayyab
RHRafaqat Hussain
Rafaqat Hussain
AAAlhafez M. Alraih
Alhafez M. Alraih

24 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKShoaib Khan
Shoaib Khan
TITayyiaba Iqbal
Tayyiaba Iqbal
RHRafaqat Hussain
Rafaqat Hussain
Yousaf KhanYousaf Khan
Yousaf Khan
ZFZanib Fiaz
Zanib Fiaz
HDHnay Darwish
Hnay Darwish
Objective: To synthesize hybrid compounds of indole and oxadiazole in search of highly effective anti-diabetic therapeutic agent. Methods: With the goal of advancing diabetes research, our group designed and synthesized a library of 15 compounds based on indole-derived oxadiazole bearing varied substituted thiazolidinone via a multistep synthetic route. 13C-NMR, 1H-NMR and HREI-MS were applied for the characterization of all the synthesized compounds. Their biological inhibitory activity against diabetic enzymes, i.e., α-amylase and α-glucosidase was also determined. Results: Compound 7, 9 and 15 exhibited excellent inhibition against α-amylase and α-glucosidase than the standard acarbose (IC50 = 8.50 ± 0.10 µM for α-amylase and 9.30 ± 0.30 µM for α-glucosidase. To ensure the inhibitory actions of these potent analogs in molecular docking, an in silico approach was used. To determine the drug likeness of the reported analogs, an ADMET investigation was also carried out to explore the nature of the designed compounds if used as a drug. Conclusion: Fluoro-substituted analog 15 has stronger inhibition profile against both enzymes. All the potent compounds can be used as effective anti-diabetic therapeutic agents in future.